- Home » News and EventsPage 3
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent to Present on Integrated UpTempo℠ Gene Therapy Development Platform at Upcoming ASGCT Annual Meeting
May 16, 2023
George Buchman, Ph.D., will present at the upcoming 26th Annual Meeting of the American Society of Gene and Cell Therapy, which is being held in Los Angeles on May 16-20, 2023.
Catalent Chief Scientific Officer to Present at Upcoming Symposium of the International Consortium for Advanced Medicines Manufacturing
Apr 20, 2023
Julien Meissonnier will present at the upcoming 4th Symposium of the International Consortium for Advanced Medicines Manufacturing (ICAMM), to be held at the Royal Sonesta Hotel, Cambridge, Massachusetts, on April 27 – 28, 2023.
Catalent Experts to Co-Host Workshops on Supply Chain Management at Upcoming Global Clinical Supplies Group Conference
Apr 13, 2023
Catalent today announced that two of its clinical supply experts are to co-host workshop sessions at the upcoming Global Clinical Supplies Group (GCSG) Conference, to be held in Orlando, Florida, on April 23 – 26, 2023.
Catalent Commences Construction of New $20M Expansion to its Clinical Supply Facility in Schorndorf, Germany
Apr 6, 2023
Catalent today announced that it has begun construction of a $20 million expansion project at its clinical supply facility in Schorndorf, Germany.
Accelerated Development and Manufacturing of Oral Small Molecules to be Discussed by Catalent Applied Drug Delivery Institute and JLABS
Mar 30, 2023
The Catalent Applied Drug Delivery Institute, which was established as a cross-industry consortium to accelerate the adoption of advanced drug delivery technologies, announces that it will hold a symposium in affiliation with Johnson & Johnson Innovation – JLABS (JLABS).
Catalent Launches New Oral Developability Assessment and Manufacturing Solution to Advance Targeted Protein Degrader Programs
Mar 29, 2023
The launch of the ProteoSuiteSM Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into clinical trials.
Harm Reduction Therapeutics and Catalent Sign Commercial Supply Agreement for Naloxone Nasal Spray to Reverse Opioid Overdoses
Mar 23, 2023
Under its terms, Catalent will manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive™ (3.0 mg), for the emergency treatment of known or suspected opioid overdose.
Catalent and Bhami Research Laboratory Enter into Licensing Agreement for Technology to Deliver High-Concentration Biologics Subcutaneously
Mar 16, 2023
Under the terms of the agreement, Catalent is authorized to collaborate with its customers to evaluate BRL’s formulation technology to reduce viscosity and deliver high-concentration biologic products.
Catalent and Grünenthal Announce Successful Collaboration to Facilitate Expedited Clinical Development Timelines
Mar 15, 2023
Catalent today announced their successful formulation design and clinical-phase manufacturing collaboration for an orally dosed small molecule in Grünenthal’s pipeline.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.